Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies-Reference-Cited by-同舟云学术

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Published:2021-11 Issue:11 Volume:32 Page:1445-1447
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pommeret F.,Colomba J.,Bigenwald C.,Laparra A.,Bockel S.,Bayle A.,Michot J.-M.,Hueso T.,Albiges L.,Tiberghien P.,Marot S.,Jary A.,Lacombe K.,Barlesi F.,Griscelli F.,Colomba E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference7 articles.

1. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial;Gottlieb;JAMA,2021

2. Dougan, M. Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Paper presented at the 28th Conference on Retroviruses and Opportunistic Infections. March 9, 2021; Virtual.

3. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients;Vijenthira;Blood,2020

4. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer;Bange;Nat Med,2021

5. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient;Lohr;Clin Infect Dis,2021

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02

2. Combination of spironolactone and DPP-4 inhibitors for treatment of SARS-CoV-2 infection: a literature review;Archives of Virology;2024-05-16

3. Anti-Spike Monoclonal Antibody Monotherapies and Immune Escape Risk Minimization Strategies;Clinical Infectious Diseases;2024-05-13

4. COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches;Cell Communication and Signaling;2024-02-15

5. Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2–Infected Hamsters;The Journal of Infectious Diseases;2024-01-12